

Financial news for PRAH dated on 2020-05-05: UBS Maintains Neutral on PRA Health Sciences, Lowers Price Target to \$101

Financial news for PRAH dated on 2020-05-04: Baird Maintains Outperform on PRA Health Sciences, Lowers Price Target to \$101

Financial news for PRAH dated on 2020-05-01: Credit Suisse Maintains Outperform on PRA Health Sciences, Lowers Price Target to \$113

Financial news for PRAH dated on 2020-05-01: William Blair Downgrades PRA Health Sciences to Market Perform

Financial news for PRAH dated on 2020-04-30: PRA Health Sciences Sees Q2 Sales \$705M-\$740M Vs. \$684.43M Est., EPS \$0.75-\$0.90 Vs. \$0.95 Est.

Financial news for PRAH dated on 2020-04-30: PRA Health Sciences Withdraws Full-Year FY20 Guidance

Financial news for PRAH dated on 2020-04-30: PRA Health Sciences Q1 EPS \$1.050 Beats \$1.020 Estimate, Sales \$783.708M Beat \$757.010M Estimate

Financial news for PRAH dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for PRAH dated on 2020-04-28: UBS Maintains Neutral on PRA Health Sciences, Lowers Price Target to \$103

Financial news for PRAH dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for PRAH dated on 2020-03-26: Barclays Maintains Overweight on PRA Health Sciences, Lowers Price Target to \$114

Financial news for PRAH dated on 2020-03-24: The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

Financial news for PRAH dated on 2020-03-23: Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.

Financial news for PRAH dated on 2020-03-23: Jefferies Maintains Buy on PRA Health Sciences, Lowers Price Target to \$89

Financial news for PRAH dated on 2020-03-20: The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company

Financial news for PRAH dated on 2020-03-19: Stocks That Hit 52-Week Lows On Thursday

Financial news for PRAH dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for PRAH dated on 2020-03-17: SunTrust Robinson Humphrey Maintains Buy on PRA Health Sciences, Lowers Price Target to \$89

Financial news for PRAH dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for PRAH dated on 2020-03-13: Stocks That Hit 52-Week Lows On Friday

Financial news for PRAH dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for PRAH dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for PRAH dated on 2020-02-21: Baird Maintains Outperform on PRA Health Sciences, Raises Price Target to \$128

Financial news for PRAH dated on 2020-02-20: PRA Health Sciences Sees Q1 EPS \$1.05-\$1.15 Vs \$1.29 Estimate, Sales \$765M-\$787M Vs \$789.18M Estimate; FY20 EPS \$5.77-\$5.97 Vs \$5.1 Estimate, Sales \$3.23B-\$3.36B Vs \$.2.21B Estimate

Financial news for PRAH dated on 2020-02-20: PRA Health Sciences Q4 EPS \$1.54 Beats \$1.47 Estimate, Sales \$800.24M Beat \$795.56M Estimate

Financial news for PRAH dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for PRAH dated on 2020-02-20: Earnings Scheduled For February 20, 2020

Financial news for PRAH dated on 2020-02-16: The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions

Financial news for PRAH dated on 2020-01-07: Citigroup Initiates Coverage On PRA Health Sciences with Neutral Rating, Announces \$120 Price Target

Financial news for PRAH dated on 2019-11-14: Wolfe Research Upgrades PRA Health Sciences to Outperform

Financial news for PRAH dated on 2019-10-30: PRA Health Raises FY19 Adj. EPS Guidance From \$4.93-\$5.08 To \$5.07-\$5.12 vs \$5.07 Est.

Financial news for PRAH dated on 2019-10-30: PRA Health Sciences Reaffirms FY19 Sales Guidance \$3.02B-\$3.10B vs \$3.06B Est.

Financial news for PRAH dated on 2019-10-30: PRA Health Sciences Q3 EPS \$1.32 Beats \$1.29 Estimate, Sales \$780.7M Beat \$771.3M Estimate

Financial news for PRAH dated on 2019-09-13: UPDATE: KeyBanc On PRA Health Sciences Also Notes 'By our models, PRAH should be able to generate revenue growth of 8%+ and EBITDA growth of 12%+ in 2020 even in the face of some integration headwinds at Symphony Health'

Financial news for PRAH dated on 2019-09-13: UPDATE: KeyBanc Maintains Overweight On PRA Health Sciences, Announces \$118 'after follow-up conversations with management and with the stock trading at a sizable discount'

Financial news for PRAH dated on 2019-09-13: Benzinga's Top Upgrades, Downgrades For September 13, 2019

Financial news for PRAH dated on 2019-09-13: KeyBanc Upgrades PRA Health Sciences to Overweight, Announces \$118 Price Target

Financial news for PRAH dated on 2019-09-04: Barclays Maintains Overweight on PRA Health Sciences, Raises Price Target to \$118

Financial news for PRAH dated on 2019-09-04: PRA Health Sciences Prices Secondary Offering of 6.6M Shares @\$97.50/Share

Financial news for PRAH dated on 2019-09-03: PRA Health Sciences Announces \$500M Share Repurchase Program

Financial news for PRAH dated on 2019-08-19: PRA Health Sciences Announces Strategic Alliance Between Symphony Health And Close-Up International

Financial news for PRAH dated on 2019-08-06: Shares of diagnostics and research companies are trading higher in sympathy with Syneos Health, which reported strong Q2 results and raised FY19 guidance.

Financial news for PRAH dated on 2019-07-31: PRA Health Sciences shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for PRAH dated on 2019-07-31: PRA Health Sciences Q2 EPS \$1.22 Beats \$1.18 Estimate, Sales \$763.3M Beat \$762.73M Estimate

Financial news for PRAH dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for PRAH dated on 2019-05-03: KeyBanc Downgrades PRA Health Sciences, Inc. - Common Stock to Sector Weight

Financial news for PRAH dated on 2019-05-01: PRA Health Sciences Reaffirms FY19 Revenue Guidance Of \$3.09-3.2 Bln Vs. \$3.14 Bln Estimate, Reaffirms FY19 Adj. EPS Guidance Of \$4.93-5.08/Share Vs. \$5.02 Estimate

Financial news for PRAH dated on 2019-05-01: PRA Health Sciences, Inc. - Common Stock Q1 EPS \$1.1 Beats \$1.06 Estimate, Sales \$722 M Miss \$732.26M Estimate

Financial news for PRAH dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for PRAH dated on 2019-03-06: PRA Health Sciences Filing Shows Registration For Common Stock Offering Via Selling Shareholders, No Size Disclosed

Financial news for PRAH dated on 2019-02-28: Baird Maintains Outperform on PRA Health Sciences, Raises Price Target to \$122

Financial news for PRAH dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for PRAH dated on 2019-02-27: PRA Health Sciences, Inc. - Common Stock Q4 Adj. EPS \$1.31 Beats \$1.27 Estimate, Sales \$729.6M Miss \$741.59M Estimate

Financial news for PRAH dated on 2019-02-27: Earnings Scheduled For February 27, 2019

Financial news for PRAH dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for PRAH dated on 2018-12-07: Jim Cramer Shares His Thoughts On JPMorgan, PRA Health Sciences And Funko

Financial news for PRAH dated on 2018-12-04: Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018

Financial news for PRAH dated on 2018-11-30: Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018

Financial news for PRAH dated on 2018-10-31: PRA Health Reaffirms FY18 Adj. EPS Guidance \$4.22-\$4.27 vs \$4.19 Estimate, Sales \$2.87B-\$2.92B vs \$2.91B Est.

Financial news for PRAH dated on 2018-10-31: PRA Health Sciences, Inc. - Common Stock Q3 EPS \$1.13 Beats \$1.07 Estimate, Sales \$717.596M Miss \$726.88M Estimate

Financial news for PRAH dated on 2018-09-17: Stocks Which Set New 52-Week High Friday, September 14th

Financial news for PRAH dated on 2018-09-14: Stocks Which Set New 52-Week High Yesterday, September 13th

Financial news for PRAH dated on 2018-09-14: The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut

Financial news for PRAH dated on 2018-09-13: Stocks Which Set New 52-Week High Yesterday, September 12

Financial news for PRAH dated on 2018-09-13: The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

Financial news for PRAH dated on 2018-09-12: Stocks Which Set New 52-Week High Yesterday, September 11th

Financial news for PRAH dated on 2018-09-11: The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces \$175M Offering, Leadership Transition At Insulet

Financial news for PRAH dated on 2018-09-06: Stocks Which Set New 52-Week High Yesterday, September 5th

Financial news for PRAH dated on 2018-08-07: PRA Health Sciences Secondary 6.5M Share Offering By KKR AAffiliate Priced At \$101.50

Financial news for PRAH dated on 2018-08-06: PRA Health Sciences Announces 6.5M Share Common Stock Secondary Offering

Financial news for PRAH dated on 2018-08-02: Barclays Maintains Overweight on PRA Health Sciences, Raises Price Target to \$115

Financial news for PRAH dated on 2018-08-01: PRA Health Sciences Sees FY18 Adj. EPS \$4.13-\$4.23 vs \$4.12 Est., Sales \$2.87B-\$2.92B vs \$2.92B Est.

Financial news for PRAH dated on 2018-08-01: PRA Health Sciences, Inc. Q2 Adj. EPS \$1.00 Beats \$0.96 Estimate, Sales \$722.8M Beat \$709.93M Estimate

Financial news for PRAH dated on 2018-07-27: Stocks Which Set New 52-Week High Yesterday, July 26th:

Financial news for PRAH dated on 2018-07-27: Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

Financial news for PRAH dated on 2018-07-26: Stocks Which Set New 52-Week High Yesterday, July 25th

Financial news for PRAH dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for PRAH dated on 2018-07-23: Stocks Which Set New 52-Week Highs Friday

Financial news for PRAH dated on 2018-07-13: Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

Financial news for PRAH dated on 2018-04-25: PRA Health Sciences Promotes Michael Bonello to CFO As Linda Baddour Retires

Financial news for PRAH dated on 2018-04-25: PRA Health Reaffirms FY18 Sales \$2.84B-\$2.95B vs \$2.91B Est., Adj. EPS \$4.00-\$4.15 vs \$4.12 Est.

Financial news for PRAH dated on 2018-04-25: PRA Health Q1 Adj. EPS \$0.85 Beats \$0.84 Est., Sales \$701.84M Beats \$694.84M Est.

Financial news for PRAH dated on 2018-04-02: Using Social Media To Accelerate Drug Development: 'The Only Way To Change The Paradigm'

Financial news for PRAH dated on 2018-02-22: Credit Suisse Maintains Outperform on PRA Health Sciences, Raises price target to \$104.00

Financial news for PRAH dated on 2018-02-21: PRA Health Sciences Reports Q4 Adj. EPS \$1.04 vs \$1.03 Est., Sales \$655.9M vs \$472.4M Est.

Financial news for PRAH dated on 2018-02-21: Earnings Scheduled For February 21, 2018

Financial news for PRAH dated on 2018-01-24: Benzinga's Top Upgrades, Downgrades For January 24, 2018

Financial news for PRAH dated on 2018-01-24: Mizuho Downgrades PRA Health Sciences to Neutral

Financial news for PRAH dated on 2017-12-15: Mitsubishi UFJ Initiates Coverage On PRA Health Sciences with Overweight Rating, Announces \$102.00 Price Target

Financial news for PRAH dated on 2017-12-11: Benzinga's Top Upgrades, Downgrades For December 11, 2017

Financial news for PRAH dated on 2017-12-11: Barclays Initiates Coverage On PRA Health Sciences with Overweight Rating, Announces \$94.00 Price Target

Financial news for PRAH dated on 2017-10-25: PRA Health Sciences Reaffirms FY 2017 Guidance

Financial news for PRAH dated on 2017-10-25: PRA Health Sciences Q3 Adj. EPS \$0.88 vs \$0.85 Est., Sales \$598.5M vs \$484.3M Est.

Financial news for PRAH dated on 2017-09-21: Mizuho Initiates Coverage On PRA Health Sciences with Buy Rating, Announces \$82.00 Price Target

Financial news for PRAH dated on 2017-08-09: 22 Biggest Mid-Day Losers For Wednesday

Financial news for PRAH dated on 2017-08-09: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PRAH dated on 2017-08-09: PRA Health Sciences Prices 10M Share Secondary, Price Not Disclosed

Financial news for PRAH dated on 2017-08-09: PRA Health Sciences Says Selling Stockholders are Offering 10M Shares of Co's Common Stock; PRA Won't Receive Any Proceeds from Sale -424B7

Financial news for PRAH dated on 2017-08-08: PRA Health Sciences Reports Offering Of 10M Shares Of Common Stock

Financial news for PRAH dated on 2017-08-07: PRA Health Sciences Reports Q2 Adj. EPS \$0.79 vs. \$0.74 Est., Sales \$533.7M May Not Compare To \$447.79M Est.

Financial news for PRAH dated on 2017-08-07: Earnings Scheduled For August 7, 2017

Financial news for PRAH dated on 2017-06-29: Jefferies Highlights A Pair Trade In Pharma: Buy ICON, Hold Tight On INC Research

Financial news for PRAH dated on 2017-06-26: Benzinga's Top Upgrades, Downgrades For June 26, 2017

Financial news for PRAH dated on 2017-06-26: Bank of America Initiates Coverage On PRA Health Sciences with Buy Rating, Announces \$89.00 Price Target

Financial news for PRAH dated on 2017-06-19: PRA Health Sciences and Jumo Report Partnership For Pediatric Clinical Development

Financial news for PRAH dated on 2017-05-11: DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme

Financial news for PRAH dated on 2017-04-25: PRA Health Sciences Adj. \$0.62 vs \$0.60 Est., Sales 4487.76M vs \$419.5M Est.

Financial news for PRAH dated on 2017-02-27: Benzinga's Top Upgrades, Downgrades For February 27, 2017

Financial news for PRAH dated on 2017-02-27: Avondale Partners Upgrades PRA Health Sciences To Market Perform

Financial news for PRAH dated on 2017-02-22: PRA Health Sciences Reports Q4 Adj. EPS \$0.71 vs. \$0.64 Est., Rev. \$472M vs. \$405M Est.

Financial news for PRAH dated on 2017-02-06: Benzinga's Top Upgrades, Downgrades For February 6, 2017

Financial news for PRAH dated on 2017-02-06: Credit Suisse Upgrades PRA Health Sciences To Outperform

Financial news for PRAH dated on 2016-11-29: PRA Health Sciences Shares Gap Down on Volume

Financial news for PRAH dated on 2016-11-10: PRA Health Sciences, Inc. Announces Secondary Offering of 7,500,000 Shares of Common Stock

Financial news for PRAH dated on 2016-11-02: PRA Health Sees FY16 Rev. \$1.568-\$1.573B vs. Est. \$1.57B, EPS \$2.45-\$2.48 vs. Est. \$2.47

Financial news for PRAH dated on 2016-11-02: PRA Health Sciences Reports Q3 EPS \$0.64 vs. Est. \$0.64, Rev. \$399.8M vs. Est. \$394.8M

Financial news for PRAH dated on 2016-09-06: UBS Downgrades PRA Health Sciences to Neutral

Financial news for PRAH dated on 2016-07-28: PRA Health Sciences Reports Q2 EPS \$0.63 vs. Est. \$0.58, Rev. \$394.2M vs. Est. \$381.25M

Financial news for PRAH dated on 2016-06-21: Benzinga's Top Initiations

Financial news for PRAH dated on 2016-06-21: PRA Health Shares Initiated Neutral By Credit Suisse

Financial news for PRAH dated on 2016-06-21: First Analysis Initiates Coverage on PRA Health Sciences at Equal-weight

Financial news for PRAH dated on 2016-06-21: Credit Suisse Initiates Coverage on PRA Health Sciences at Neutral, Announces \$43.00 PT

Financial news for PRAH dated on 2016-06-13: KeyBanc Expecting PRA Health Sciences To Beat Estimates, Upgrades To Overweight

Financial news for PRAH dated on 2016-06-13: Benzinga's Top Upgrades

Financial news for PRAH dated on 2016-06-13: KeyBanc Upgrades PRA Health Sciences to Overweight

Financial news for PRAH dated on 2016-05-04: Citigroup Upgrades PRA Health Sciences to Buy, Raises PT to \$53.00

Financial news for PRAH dated on 2016-05-03: 12 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PRAH dated on 2016-05-02: PRA Health Sciences Reports Offering of 5M Snares of Common Stock

Financial news for PRAH dated on 2016-04-27: UPDATE: PRA Health Raises FY16 Adj. EPS Outlook from \$2.32-\$2.42 to \$2.41-\$2.48 vs \$2.38 Est.

Financial news for PRAH dated on 2016-04-27: PRA Health Sciences Reports Q1 Adj. EPS \$0.55 vs \$0.53 Est., Sales \$372.3M vs \$372.2M Est.; Raises Outlook

Financial news for PRAH dated on 2016-03-31: PRA Health Sciences Reports Received Recognition from ViE

Financial news for PRAH dated on 2016-03-28: Benzinga's Top Upgrades

Financial news for PRAH dated on 2016-03-28: SunTrust Robinson Humphrey Upgrades PRA Health Sciences to Buy, Raises PT to \$51.00

Financial news for PRAH dated on 2016-03-02: UPDATE: PRA Health Sciences Reports 5M Share Secondary Offering

Financial news for PRAH dated on 2016-03-02: PRA Health Sciences Files Stock Offering For Selling Shareholders

Financial news for PRAH dated on 2016-02-24: PRA Health Sees FY16 Service Sales Growth 11-14%, Adj. EPS \$2.32-\$2.42 vs \$2.19 Est.

Financial news for PRAH dated on 2016-02-24: PRA Health Reports Q4 Adj. EPS \$0.59 vs \$0.49 Est., Sales \$362.3M vs \$353M Est.

Financial news for PRAH dated on 2015-12-15: Stocks Hitting 52-Week Highs

Financial news for PRAH dated on 2015-12-07: WuXi PharmaTech, PRA Health Sciences Restructure Relationship in China for Delivery of Clinical Trial Management Services

Financial news for PRAH dated on 2015-11-19: Benzinga's Top Initiations

Financial news for PRAH dated on 2015-11-19: SunTrust Robinson Humphrey Initiates Coverage on PRA Health Sciences at Neutral, Announces \$47.00 PT

Financial news for PRAH dated on 2015-11-04: Avondale Partners Downgrades PRA Health Sciences to Underperform

Financial news for PRAH dated on 2015-11-02: PRA Health Sciences Raises FY15 EPS From \$1.75-\$1.85 To \$1.89-\$1.92/Share

Financial news for PRAH dated on 2015-11-02: PRA Health Sciences Reports Q3 EPS \$0.52 vs. Est. \$0.45, Rev. \$345.1M vs. Est. \$346.05M

Financial news for PRAH dated on 2015-09-29: PRA Health Sciences Collaborates With AMR to Accelerate Vaccine Development

Financial news for PRAH dated on 2015-08-14: Credit Suisse Assumes PRA Health Sciences at Outperform, Announces \$47.00 PT

Financial news for PRAH dated on 2015-07-27: PRA Health Raises FY15 Adj. EPS Outlook from \$1.62-\$1.72 to \$1.75-\$1.85 vs \$1.67 Est., Sales Affirmed in \$1.34B-\$1.39B Range

Financial news for PRAH dated on 2015-07-27: PRA Health Sciences Reports Q2 Adj. EPS \$0.47 vs \$0.40 Est., Service Sales \$336.5M vs \$336.7M Est.

Financial news for PRAH dated on 2015-07-02: KeyBanc Initiates PRA Health Sciences With Sector Weight

Financial news for PRAH dated on 2015-07-02: Benzinga's Top Initiations

Financial news for PRAH dated on 2015-07-02: KeyBanc Initiates Coverage on PRA Health Sciences at Sector Weight

Financial news for PRAH dated on 2015-06-15: PRA Continues the Transformation of Clinical Trials With Predictiv(TM)

Financial news for PRAH dated on 2015-05-27: Jefferies Boosts Targets Across Pharmaceutical Service Stocks

Financial news for PRAH dated on 2015-05-06: PRA Health Sciences Reports Adj EPS \$0.41 Vs Est \$0.31, Sales \$388.6M Vs Est \$329.76M, Sees 2015 Adj EPS \$1.62-\$1.72

Financial news for PRAH dated on 2015-05-06: PRA Health Sciences Reports Q1 Adj. EPS \$0.41 vs \$0.31 Est.; Sees FY15 Adj. EPS \$1.62-\$1.72

Financial news for PRAH dated on 2015-04-27: Jefferies Previews Booming Biotech Earnings

Financial news for PRAH dated on 2015-03-30: PRA Health Expands Global Phase I Patient Strategy

Financial news for PRAH dated on 2015-02-18: PRA Health Reports Q4 Adj. EPS \$0.35 vs

\$0.30 Est.; Sees FY15 Adj. EPS \$1.35-\$1.45

Financial news for PRAH dated on 2014-12-22: William Blair Initiates Coverage on PRA Health Sciences at Outperform

Financial news for PRAH dated on 2014-12-08: Analyst Roundup On PRA Health Sciences After Quiet Period Ends

Financial news for PRAH dated on 2014-12-08: UPDATE: Citigroup Initiates Coverage On PRA Health Sciences On Ingredients For Success

Financial news for PRAH dated on 2014-12-08: Benzinga's Top Initiations

Financial news for PRAH dated on 2014-12-08: Jefferies Initiates PRA Health Sciences At Buy

Financial news for PRAH dated on 2014-12-08: Credit Suisse Initiates Coverage on PRA Health Sciences at Outperform, Announces \$27.00 PT

Financial news for PRAH dated on 2014-12-08: Citigroup Initiates Coverage on PRA Health Sciences at Neutral, Announces \$24.00 PT

Financial news for PRAH dated on 2014-12-08: UBS Initiates Coverage on PRA Health Sciences at Buy, Announces \$28.00 PT

Financial news for PRAH dated on 2014-12-08: Baird Initiates Coverage on PRA Health Sciences at Outperform, Announces \$28.00 PT

Financial news for PRAH dated on 2014-12-08: Jefferies Initiates Coverage on PRA Health Sciences at Buy, Announces \$27.00 PT

Financial news for PRAH dated on 2014-11-13: Shares of PRA Health Sciences Open for Trade at \$18.55/Share, IPO Priced at \$18

Financial news for PRAH dated on 2014-11-13: Expected IPOs For November 13

Financial news for PRAH dated on 2014-11-03: PRA Health Sciences Expects 18.6M Share IPO to Price \$20.00-\$23.00/Share